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also to extracellular gliding and cell inva-
sion. Monitoring how and where these
filaments emerge, elongate, and recycle
will certainly require future imaging adjust-
ments to increase signal sensitivity,
speed, and resolution. Thanks to the
great achievement in generating a tool
that all the community was waiting for,
and in conjunction with photoactivation
and inactivation-based approaches, and
super-resolution live-cell imaging, the
mystery of the actin contribution to the
lytic cycle of tachyzoites might be finally
elucidated in the near future.
Periz et al. [7] now describe unique F-
actin networks that (1) connect one
daughter to the other, and presumably
contribute to the rosette pattern while
allowing interparasite communication,
and (2) collapse while F-actin retreats to
the RB before the networks reform again
and expand throughout the PV. Break-
down of the network also precedes
tachyzoite egress from the PV and the
host cell while residual F actin can still
be seen within the RB (Figure 1).
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In this article, the four coordinators
of neglected tropical disease
(NTD) drug development projects
funded under the European Com-
mission (EC) Framework Pro-
gramme 7 argue that the EC
should reassess their funding
strategy to cover the steps neces-
sary to translate a lead compound
into a drug candidate for testing in
clinical trials, and suggest ways in
which this might be achieved.
EC Funding of NTD Drug
Development
The EC has consistently and substantially
supported research into NTDs, starting
well before the London Declaration of
2012 (http://unitingtocombatntds.org/
resource/london-declaration), which put
the control or elimination of NTDs at the
forefront of global efforts to ‘chart a newcourse toward health and sustainability
among the world’s poorest communities
to a stronger, healthier future’. However,
grants for research on NTDs represented
only 11% of the total funding for infectious
diseases during the EC Framework
Programmes (FP) 5 to 7 up to 2013,
70% going to the so-called ‘Big Three’
diseases: malaria, tuberculosis, and
HIV/AIDS [1]. The development of new
drugs is particularly important in order
to circumvent problems with current
treatments, including drug resistance,
severe side-effects, or exacting dosing
schedules. There is a recognized need
to identify new chemical entities (NCEs)
as candidate drugs in order to both
improve patient care and meet targets
for elimination, particularly of neglected
parasitic diseases [2]. Nevertheless, only
6% of the EC infectious disease funding
was dedicated to drug development.
EC FP7 Drug Discovery Projects
The EC has been notably successful in
bringing together large, multinational
research networks. Four such consortia,
with the acronyms NMTrypI (http://
fp7-nmtrypi.eu), KINDReD (http://
kindred-fp7.com/), A-ParaDDisE (http://
a-paraddise.cebio.org/), and PDE4NPD
(www.pde4npd.eu), involving more than
50 teams in Europe, Africa, India, South
America, Australia, and the USA, were
funded in the last call under FP7 related
to drug development in neglected infec-
tious diseases. The projects targeted the
major chronic parasitic diseases leish-
maniasis, Chagas disease, sleeping sick-
ness, schistosomiasis, and malaria.
Together, these diseases affect more
than a billion people worldwide, cause
hundreds of thousands of deaths, and
are major contributors to the poverty trap
in the countries concerned [2]. The proj-
ects were given the following objectives:
 To establish a common drug-discovery
platform that should have the capacity
to undertake screening of compound
libraries, lead development.
 To test validated hit compounds in rel-
evant animal models as well asTrends in Parasitology, August 2017, Vol. 33, No. 8 581
toxicology and safety testing of new
drug candidates.
The four projects pursued distinct strate-
gies for drug discovery, involving both
phenotypic screening, target-based
methods, and repurposing of existing
approved drugs, and have all made sig-
nificant progress. Based on the criteria
for the selection of ‘hit’ and ‘lead’ com-
pounds, recently defined [3], well over
100 hits have been identified of which
more than 10 can so far be defined as
lead compounds with promising profiles
in animal studies and significant potential
for further development. These numbers
will grow as the projects reach term. In
addition, novel drug targets have been
identified and validated for each of the
parasites studied, homology models
and crystal structures of target enzymes
have been resolved, and new chemical
entities identified as potential drugs of
interest both in NTDs and other
pathologies.
Importantly, as suggested by the EC at
the time of funding, the four consortiaDrug
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Figure 1. The Drug Discovery Pipeline.
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throughout the course of their projects
under the umbrella of common ‘Synergy’
activities. These involved regular discus-
sions, a joint symposium in 2016, com-
mon partner teams and/or external
advisory board members, resource pool-
ing, and a common data storage platform
(https://fp7h-synergy.h-its.org/). This has
enabled them to adopt a common strat-
egy to face the challenge of ensuring that
the advances made will not be lost once
the current projects come to an end. Cru-
cially, support is needed for developing hit
and lead compounds from in vivo animal
studies through preclinical testing up
to and including phase I clinical trials.
This involves rigorous pharmacokinetic,
pharmacodynamic, and toxicity studies
(Absorption, Distribution, Metabolism,
Excretion, and Toxicity; ADMET) and
drug production according to Good Lab-
oratory Practice/Good Manufacturing
Practice (GLP/GMP) standards (Figure 1).
No funding opportunities exist for these
types of study in the current EC research
programme, Horizon2020 (H2020),c
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 modelingwhich at present supports only clinical
trials through the European & Developing
Countries Clinical Trials Partnership
(EDCTP). While NTDs have been added
to the remit of the EDCTP, the support
proposed in the business plan until
2024 (http://www.edctp.org/web/app/
uploads/2016/12/EDCTP-Strategic-
Business-Plan-2014-2024.pdf) is restric-
tive, whether for diagnostics, vaccine or
drug development. Support for the latter
concerns predominantly phase II to phase
III clinical trials, with a focus on drug com-
binations, and only in sub-Saharan Africa
(ruling out support for clinical trials on some
important NTDs like Chagas disease).
Moreover, only in the case of diseases
where treatments are ‘inadequate or lack-
ing’ will phase I trials be funded. This leaves
a yawning ‘funding gap’ between hit-to-
lead development and clinical trials.
Funding Initiatives for NTD Drug
Development
Mechanisms do exist to fill the funding
gap and take validated lead compounds
through the complex and costly early-clin-
ical phase of testing. These are mainly
nonprofit initiatives funded by various
sources, including, for example, the Bill
& Melinda Gates foundation (http://www.
gatesfoundation.org/), governments, and
the pharmaceutical industry. Examples
are the Drugs for Neglected Diseases Ini-
tiative (DNDi; http://www.dndi.org/),
WIPO Re:search (http://www.wipo.int/
research/en/), and the Medicines for
Malaria Venture (https://www.mmv.org/
). The DNDi has overseen the progress
of fexinidazole to phase IIb/III clinical trials
for the treatment of human African try-
panosomiasis, to phase IIa for the treat-
ment of Chagas disease, and to phase IIa
in combination with miltefosine for the
treatment of leishmaniasis, and has other
leads in the pipeline for NTDs, as well as
for other diseases such as paediatric HIV
and hepatitis C. Nevertheless, due to the
high attrition rate for candidate drugs at all
stages of the development pipeline, it is
advantageous to have more candidates
to feed into it. This again implies
appropriate funding: a pooled R&D fund
has been proposed by the WHO [4] but
this remains theoretical. The absence of
such a large pooled funding mechanism
and the fragmentation of current efforts
are to be deplored [2,5].
How the EC Can Make a
Difference
The considerable contribution of the EC-
funded programmes to NTD research is
not in question. It is also clear that
emphasis has previously been placed
on basic research, but that this should
now shift in order to address the gaps in
the pipelines for the development of
drugs, vaccines, and diagnostics. The
most obvious gap separates drug hit
and lead development from the type of
clinical trial funded by the EDCTP. The
next logical step for the drug develop-
ment investment strategy of the EU
would be to fund a call within H2020,
to build upon the synergy developed in
the last FP7 call. This would enable con-
tinued interaction between academia
and small and medium-sized enterprises
by creating a platform to take on the task
of bridging the gap between lead opti-
mization and early-stage clinical trials
(phases I–II). Lead compounds devel-
oped by the four consortia, but also from
other sources (e.g., teams participating
in the current EC-funded COST 1307
initiative) would feed the platform regard-
less of the parasitic disease targeted,
overcoming the problem of fragmenta-
tion amongst groups in the field and
removing replication of effort. While this
should not replace funding of basic
research, it would lead to an increase
in the density of the different stages of
preclinical testing and in the numbers
of candidates entering phase I clinical
trials. In this way the previous investment
in NTD drug discovery would be
consolidated.
While it is evident that no single funder can
completely cover the whole drug devel-
opment pipeline, targeted funding, as
suggested here, could attract supportfrom other sources, including industry,
foundations, and nongovernmental orga-
nizations, and collaborations between
these stakeholders should be sought.
Finally, the cooperation of the pharma-
ceutical industry, whose expertise is
essential for any drug to finally reach
the clinic, could be engineered through
the Innovative Medicines Initiative (IMI),
cofunded by the EC and industry, by add-
ing NTD drug development to the IMI
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The malaria parasite has a func-
tional heme-biosynthetic pathway,
although it can access host hemo-
globin-heme. The heme pathway is
dispensable for blood stages, but
essential in the mosquito stages
which do not acquire hemoglo-
bin-heme. We propose that the
blood stage parasites maintain a
dynamic heme pool through multi-
ple back-up mechanisms.Heme Pathway in the Malaria
Parasite
Heme-containing cytochromes are
essential for the functioning of the elec-
tron transport chain (ETC) in the malaria
parasite. The ETC is required to support
pyrimidine biosynthesis in the blood
stages, whereas in the sexual and liver
stages it is also involved in ATP genera-
tion and oxidative metabolism. The
malaria parasite acquires host hemoglo-
bin in the blood stages and digests it in
the food vacuole to generate amino acids.
Since accumulation of free heme is toxic,
it stores the excess heme derived from
hemoglobin as hemozoin pigment, a bio-
crystallized form of heme-aggregates [1].
Interestingly, the parasite can synthesize
its own heme from glycine, and the entire
pathway involves three different parasite
compartments: mitochondria, apicoplast,
and cytosol (Figure 1A) [2]. Studies with
Plasmodium berghei-infected mice [3]
and Plasmodium falciparum in cultures
[4] using knockout (KO) parasites gener-
ated for d-aminolevulinic acid synthetase
(ALAS) and ferrochelatase (FC), the first
and last enzymes of heme-biosyntheticTrends in Parasitology, August 2017, Vol. 33, No. 8 583
